The European Commission has exercised its option to purchase an additional 80 million doses of mRNA-1273 for EU Member states, taking their total doses of Moderna’s mRNA-1273 to 160 million.
“We appreciate the confidence in Moderna and mRNA-1273, our COVID-19 vaccine candidate, demonstrated by this increased supply agreement with the European Commission,” said Stéphane Bancel, Chief Executive Officer of Moderna. “As we shift our focus now to prepare for the delivery of our vaccine candidate, pending a positive opinion from the EMA and other regulators, we remain as committed as ever to working with governments and partners globally to address this pandemic.”
- Shipping and Temperature Update
Modera has updated its handling guide for the distribution for mRNA-1273 to include local transport under controlled conditions in a liquid state at 2-8°C (36° to 46°F). This important update eases the logistical burden of transporting the vaccine to more remote locations and ensures that the barriers to being vaccinated are lowered. As previously announced, mRNA-1273 remains stable at standard refrigerator temperatures of 2° to 8°C (36° to 46°F) for 30 days.
- This information was shared at yesterday’s VRBPAC meeting in the United States, after which the FDA Advisory Committee voted to support emergency use for Moderna’s Vaccine Against COVID-19 in the United States.
